396
Participants
Start Date
June 2, 2020
Primary Completion Date
January 8, 2021
Study Completion Date
February 12, 2021
MSTT1041A
Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
MSTT1041A-matched Placebo
Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
UTTR1147A
Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
UTTR1147A-matched Placebo
Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
Staten Island University Hospital; Department of Pharmacy, Staten Island
Lincoln Medical Mental Health Center, The Bronx
Albany Medical Center, Albany
Lehigh Valley Health Network, Allentown
Hospital General Universitario de Guadalajara, Guadalajara
Hospital General de Tijuana, Tijuana
Virginia Commonwealth University, Richmond
Hospital Costa del Sol; Servicio de Oncologia, Marbella
WellStar Research Institute, Marietta
Bay Pines VA Medical Center - NAVREF, Bay Pines
Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca
Mercy St. Vincent Medical Center, Toledo
Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca, Guadalajara
Hospital Clinico Universitario Valladolid, Valladolid
Henry Ford Health System, Detroit
MedPharmics, Metairie
Southeast Louisiana Veterans Health Care System - NAVREF, New Orleans
DM Clinical Research - Alexandria Cardiology Clinic - ERN - PPDS, Alexandria
University of Arkansas For Medical Sciences, Little Rock
Parkland Health & Hospital System, Dallas
University of Texas Southwestern Medical Center, Dallas
Denver Health Medical Center, Denver
San Juan Oncology Associates, Farmington
Torrance Memorial Medical Center, Torrance
eStudySite - Chula Vista - PPDS, Chula Vista
eStudySite, La Mesa
Providence Portland Medical Center; Investigational Drug Services/Regional Research, Portland
Virginia Mason Medical Center, Seattle
MultiCare Institute for Research and Innovation; Clinic/Outpatient Facility, Tacoma
St. Joseph'S Regional Medical Center, Paterson
Instituto de Pesquisa Clinica Evandro Chagas FIOCRUZ, Rio de Janeiro
Santa Casa de Porto Alegre, Porto Alegre
Hospital E Maternidade Celso Pierro PUCCAMP, Campinas
Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto, São José do Rio Preto
Hospital Alemao Oswaldo Cruz, São Paulo
Instituto do Coração - HCFMUSP, São Paulo
Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, México
Instituto Nacional De Enfermedades Respiratorias INER National Institute of Respiratory Diseases, México
Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat
Hospital del Mar, Barcelona
Lead Sponsor
Biomedical Advanced Research and Development Authority
FED
Genentech, Inc.
INDUSTRY